Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
| ▸ | RYR2 | Q92736 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2226077 | 0.71 | HTR2C (0.46) | HTR2CHTR2AADRB1SIGMAR1HTR3E | |
| SCHEMBL11111087 | 0.66 | RYR2 (0.37) | HTR2CSIGMAR1RYR2 | |
| SCHEMBL3894929 | 0.63 | RYR2 (0.36) | SIGMAR1RYR2KMT2A | |
| SCHEMBL6969929 | 0.63 | RYR2 (0.40) | SIGMAR1RYR2KMT2A | |
| SCHEMBL31146716 | 0.63 | RYR2 (0.36) | HTR2CHTR2ASIGMAR1RYR2KMT2A | |
| SCHEMBL11217635 | 0.63 | MAOA (0.40) | KDM1ASIGMAR1RYR2DRD2 | |
| SCHEMBL17185647 | 0.63 | RYR2 (0.36) | SIGMAR1RYR2KMT2A | |
| SCHEMBL19674181 | 0.63 | RYR2 (0.40) | SIGMAR1RYR2KMT2A | |
| SCHEMBL11118465 | 0.63 | RYR2 (0.40) | SIGMAR1RYR2MEN1KMT2A | |
| SCHEMBL29463396 | 0.63 | MAOA (0.40) | KDM1ASIGMAR1RYR2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295112-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-09-21 | — | — | US | disclosed |
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | PFIZER INC | 2008-10-30 | — | — | US | disclosed |
| EP-1757292-A1 | Method of treating ocd and tic disorders | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| US-20050004138-A1 | Anxiety treatments with ziprasidone | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| US-20050004137-A1 | Treatment of psychotic and depressive disorders | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| EP-0931547-B1 | Piperazinyl-heterocyclic compounds in the treatment of dementia | PFIZER PROD INC (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6245766-B1 | USING A PIPERAZINE COMPOUND | PFIZER INC | 2001-06-12 | — | — | US | disclosed |
| US-6127373-A | Method of treating tourette's syndrome and obsessive compulsive disorder | PFIZER INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0931547-A1 | Piperazinyl-heterocyclic compounds in the treatment of psychiatric conditions | Pfizer Products Inc. (US) | 1999-07-28 | — | — | EP | disclosed |
| EP-0901789-A1 | Method of treating tourette's syndrome | Pfizer Products Inc. (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0279598-B1 | ARYLPIPERAZINYL-ALKYLENE-PHENYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1993-09-15 | — | — | EP | disclosed |
| EP-0281309-B1 | PIPERAZINYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| US-4891375-A | Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds | PFIZER INC. (US) | 1990-01-02 | — | — | US | disclosed |
| US-4883795-A | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1989-11-28 | — | — | US | disclosed |
| US-4831031-A | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity | PFIZER INC. (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0281309-A1 | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1988-09-07 | — | — | EP | disclosed |
| EP-0279598-A2 | Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds | PFIZER INC. (US) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004137-A1 | Treatment of psychotic and depressive disorders | SNCA, NLN, INA | HTR2C 397/4885HTR2A 232/4885KDM1A 3812/4885 |
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | MC2R, NR3C1, CRH | HTR2C 475/4885HTR2A 295/4885KDM1A 2349/4885 |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | DBH, RAP1A, GABRR1 | HTR2C 417/4885HTR2A 80/4885KDM1A 1633/4885 |
| US-20230295112-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | HTR2C 1257/4885HTR2A 2274/4885KDM1A 3373/4885 |
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | GABBR1, GABRR1, GABBR2 | HTR2C 518/4885HTR2A 179/4885KDM1A 992/4885 |
| US-20050004138-A1 | Anxiety treatments with ziprasidone | NPSR1, AVPR1B, SLC39A3 | HTR2C 493/4885HTR2A 188/4885KDM1A 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.